Oncology Today—July 6, 2026

This week’s Oncology update highlights regulatory approvals, commercialization progress, late-stage clinical development, and expanded patient access across multiple cancer types.

In Today’s Newsletter

Dive deeper

Ask Google AI

Ask ChatGPT

Ask Perplexity

Ask Grok

🧬 Alpha1H Phase 3 regulatory approval [1] [EU • 29 Jun 2026]

https://hamletbiopharma.com/pressrelease-lund-june-29th-2026-hamlet-biopharma-receives-european-regulatory-approval-for-phase-iii-study-of-alpha1h-in-bladder-cancer/
Context: The study targets low- to intermediate-risk NMIBC, following Phase 2 data with promising anti-tumor activity and favorable safety.
Key point: Hamlet BioPharma said Alpha1H received European regulatory approval for a Phase 3 study in bladder cancer.
Implication: May influence prescriber choice and payer reviews pending full data.

🤝 Innovent–Lilly China Verzenios agreement [2] [China • 30 Jun 2026]

https://en.innoventbio.com/InvestorsAndMedia/PressReleaseDetail?key=608
Context: Innovent will manage importation, marketing, distribution, and promotion, while Lilly remains MAH and handles supply and development.
Key point: Innovent Biologics and Eli Lilly entered a commercialization agreement for Verzenios (abemaciclib) in mainland China.
Implication: Signals pipeline investment and modality expansion.

🧫 PADCEV perioperative approval in Canada [3] [Canada • 29 Jun 2026]

https://www.pfizer.ca/en/media-centre/perioperative-option-approved-in-canada-for-patients-with-muscle-invasive-bladder-cancer-unable-to-receive-cisplatin-based-therapy
Context: The approval covers neoadjuvant use and continuation after radical cystectomy, supported by EV-303.
Key point: Health Canada approved PADCEV (enfortumab vedotin) plus pembrolizumab for perioperative treatment of cisplatin-ineligible MIBC.
Implication: May influence prescriber choice and payer reviews pending full data.

🫁 Taletrectinib UK MAA validation [4] [UK • 29 Jun 2026]

https://investors.nuvationbio.com/news/news-details/2026/Nuvation-Bio-Announces-Marketing-Authorisation-Application-for-Taletrectinib-for-the-Treatment-of-Advanced-ROS1-Positive-Non-Small-Cell-Lung-Cancer-Validated-in-the-United-Kingdom/default.aspx
Context: The filing uses the International Recognition Procedure and is based on TRUST-I and TRUST-II Phase 2 data.
Key point: Nuvation Bio said the MHRA validated Eisai’s UK MAA for taletrectinib in advanced ROS1-positive NSCLC.
Implication: May influence prescriber choice and payer reviews pending full data.

🇩🇪 Zepzelca launch in Germany and Austria [5] [Germany/Austria • 01 Jul 2026]

https://pharmamar.com/en/germany-and-austria-the-first-european-countries-to-commercialize-pharmamars-zepzelca-lurbinectedin-for-small-cell-lung-cancer/
Context: The EC-approved indication is first-line maintenance for adults with ES-SCLC whose disease has not progressed after induction therapy.
Key point: PharmaMar began commercial supply of Zepzelca (lurbinectedin) plus atezolizumab in Germany and Austria.
Implication: May expand screening, initiation, and follow-up at scale.

🎯 Enolen Phase 3 design feedback [6] [US • 01 Jul 2026]

https://alessatherapeutics.com/news/alessa-therapeutics-receives-positive-fda-feedback-following-type-c-meeting-on-enolens-pivotal-phase-3-trial-design/
Context: FDA said one trial versus active surveillance could support an NDA in low- to intermediate-risk localized prostate cancer.
Key point: Alessa Therapeutics received positive FDA feedback on the planned pivotal Phase 3 trial design for Enolen.
Implication: May influence prescriber choice and payer reviews pending full data.

🇰🇷 SERPLUMA approval in South Korea [7] [South Korea • 02 Jul 2026]

https://www.lotuspharm.com/en/newsroom/news-page/326
Context: Approval was supported by ASTRUM-005, which tested serplulimab plus carboplatin and etoposide.
Key point: Lotus Pharmaceutical and Henlius said MFDS approved SERPLUMA (serplulimab) for first-line ES-SCLC.
Implication: May influence prescriber choice and payer reviews pending full data.

🏥 HETRONIFLY enters NHS routine use [8] [England/Wales • 02 Jul 2026]

https://www.henlius.com/en/NewsDetails-6031-26.html
Context: The source describes serplulimab as the first NICE-recommended anti-PD-1 available through the NHS for ES-SCLC.
Key point: Henlius said HETRONIFLY (serplulimab) entered routine NHS use after a NICE recommendation.
Implication: May expand screening, initiation, and follow-up at scale.

🧭 ORPATHYS China approval in MET-amplified gastric cancer [9] [China • 02 Jul 2026]

https://www.hutch-med.com/savolitinib-gc-nmpa-approval/
Context: The indication is for patients who failed at least two prior systemic treatments, supported by a pivotal Phase 2 study.
Key point: HUTCHMED said China’s NMPA conditionally approved ORPATHYS (savolitinib) for MET-amplified advanced GC/GEJ adenocarcinoma.
Implication: May influence prescriber choice and payer reviews pending full data.

🧪 Candel opens Phase 3 AURORA trial [10] [Global • 30 Jun 2026]

https://ir.candeltx.com/news-releases/news-release-details/candel-therapeutics-announces-initiation-global-pivotal-phase-3
Context: AURORA compares aglatimagene besadenovec plus valacyclovir with continued pembrolizumab versus docetaxel, with overall survival as the primary endpoint.
Key point: Candel Therapeutics initiated the global pivotal Phase 3 AURORA trial of aglatimagene besadenovec in advanced NSCLC.
Implication: May influence prescriber choice and payer reviews pending full data.

Why it matters

• Bladder cancer saw two regulatory moves, with Alpha1H advancing toward Phase 3 in NMIBC and PADCEV plus pembrolizumab gaining Canadian perioperative approval in cisplatin-ineligible MIBC.
• Small cell lung cancer access expanded across Europe and Asia, with Zepzelca supply in Germany and Austria and serplulimab milestones in South Korea and the NHS.
• Precision oncology remained active, with taletrectinib under UK review for ROS1-positive NSCLC and savolitinib approved in China for MET-amplified GC/GEJ adenocarcinoma.
• Several updates focus on late-stage development pathways, including Enolen’s FDA-aligned Phase 3 design and Candel’s global Phase 3 AURORA launch.
• Commercial execution is central to access, including Innovent’s China role for Lilly’s Verzenios and Lotus’s South Korea rights for SERPLUMA.

🚀 Accelerate your success. Contact us now